Natco Pharma Faces USFDA Scrutiny: Chennai Plant Gets 7 Observations Amid Mixed Q2 Results!

Healthcare/Biotech

Published on 21st November 2025, 12:15 PM

Author

Simar Singh | Whalesbook News Team

Overview

Natco Pharma's Chennai API facility received seven procedural observations during a USFDA inspection (Nov 17-21). The company is confident in addressing these. This follows mixed Q2 results showing a 23.5% profit drop to ₹518 crore, though an interim dividend of ₹1.50 per share was declared.